Literature DB >> 17415709

Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells.

Hazem Ghebeh1, Asma Tulbah, Shamayel Mohammed, Naser Elkum, Suad M Bin Amer, Taher Al-Tweigeri, Said Dermime.   

Abstract

B7-H1, a co-inhibitory molecule, plays a role in immune escape of tumors. We have shown previously the expression of this molecule in breast cancer patients and demonstrated its association with high histological grade, progesterone and estrogen receptor negative status, all of which are known to have direct impact on cell proliferation. In the present work, we investigated the effect of proliferation, as measured by Ki-67 and mitotic count, on the induction of B7-H1. We used H&E stained sections to score for mitotic count in 69 breast cancer patients. Immunohistochemistry was used to investigate B7-H1 and Ki-67 expression. The relationship between B7-H1 induction and cell proliferation was further investigated in primary cultured cells. B7-H1 expression was recorded in patients with a high mitotic index (p = 0.007). There was a high significant correlation between B7-H1 expression and the presence of the proliferative marker Ki-67 (p < 0.001) indicating the association of proliferation with B7-H1 induction. Furthermore, B7-H1 was gradually induced in proliferating cells of 8/8 primary cell lines as measured by Ki-67 expression. Finally, B7-H1 was downregulated in quiescent cells and upregulated in cells stimulated with a mitogen confirming the association of proliferation with the induction of B7-H1. We have shown for the first time a direct association between proliferation and the expression of B7-H1 in breast cancer patients. The relationship between B7-H1 induction and cell proliferation was also thoroughly investigated in vitro, in which a strong link between B7-H1 expression and the presence of the proliferative Ki-67 marker was clearly demonstrated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415709     DOI: 10.1002/ijc.22703

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  69 in total

1.  CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.

Authors:  Akihiro Tsuyada; Amy Chow; Jun Wu; George Somlo; Peiguo Chu; Sofia Loera; Thehang Luu; Arthur Xuejun Li; Xiwei Wu; Wei Ye; Shiuan Chen; Weiying Zhou; Yang Yu; Yuan-Zhong Wang; Xiubao Ren; Hui Li; Peggy Scherle; Yukio Kuroki; Shizhen Emily Wang
Journal:  Cancer Res       Date:  2012-04-03       Impact factor: 12.701

2.  Senescent Breast Luminal Cells Promote Carcinogenesis through Interleukin-8-Dependent Activation of Stromal Fibroblasts.

Authors:  Huda H Al-Khalaf; Hazem Ghebeh; Rabia Inass; Abdelilah Aboussekhra
Journal:  Mol Cell Biol       Date:  2019-01-03       Impact factor: 4.272

3.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

4.  Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.

Authors:  Xavier Frigola; Brant A Inman; Christine M Lohse; Christopher J Krco; John C Cheville; R Houston Thompson; Bradley Leibovich; Michael L Blute; Haidong Dong; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

5.  Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma.

Authors:  Liancai Wang; Qingyong Ma; Xiangli Chen; Kun Guo; Junhui Li; Min Zhang
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

6.  Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

Authors:  Jun Zhou; Kathleen M Mahoney; Anita Giobbie-Hurder; Fengmin Zhao; Sandra Lee; Xiaoyun Liao; Scott Rodig; Jingjing Li; Xinqi Wu; Lisa H Butterfield; Matthias Piesche; Michael P Manos; Lauren M Eastman; Glenn Dranoff; Gordon J Freeman; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2017-05-18       Impact factor: 11.151

Review 7.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

Review 8.  Emerging role of circulating tumor cells in immunotherapy.

Authors:  Alexey Rzhevskiy; Alina Kapitannikova; Polina Malinina; Arthur Volovetsky; Hamidreza Aboulkheyr Es; Arutha Kulasinghe; Jean Paul Thiery; Anna Maslennikova; Andrei V Zvyagin; Majid Ebrahimi Warkiani
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

Review 9.  The complex role of B7 molecules in tumor immunology.

Authors:  Barbara Seliger; Francesco M Marincola; Soldano Ferrone; Hinrich Abken
Journal:  Trends Mol Med       Date:  2008-11-03       Impact factor: 11.951

10.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule.

Authors:  Hazem Ghebeh; Cynthia Lehe; Eman Barhoush; Khaldoon Al-Romaih; Asma Tulbah; Monther Al-Alwan; Siti-Faujiah Hendrayani; Pulicat Manogaran; Ayodele Alaiya; Taher Al-Tweigeri; Abdelilah Aboussekhra; Said Dermime
Journal:  Breast Cancer Res       Date:  2010-07-13       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.